The results reinforce the need for individualized, biology-driven therapeutic decisions in patients with MS. SAN DIEGO – ...
Mild traumatic brain injury (mTBI) remains a significant health concern for the US Military Health System and a threat to warfighter readiness. Although most service members (SMs) recover following an ...
The dazzling 36-month clinical data announced by uniQure (NASDAQ: QURE) showing a significant slowing of Huntington’s disease (HD) progression in patients treated with its gene therapy candidate ...
The last time I wrote an article on uniQure N.V. (QURE), it was in a Seeking Alpha article entitled "uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting." With respect to that article, ...
UniQure shares tripled, to $41.27, in early Wednesday trading after the company said it had positive topline results for a Phase I/II study of AMT-130 for the treatment of Huntington's disease, and ...
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external ...
uniQure reported positive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington’s disease. The study met its prespecified primary endpoint, with high-dose AMT-130 ...
Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and bladder control in older adults. The disorder is treated with shunt surgery, ...
Cognitive impairment is increasingly recognized in patients with cerebral venous congestion (CVC), yet the cognitive tools used are largely adapted from stroke and dementia research. This review ...
Poststroke cognitive impairment can significantly impact functional outcomes and quality of life. While comprehensive neuropsychological evaluations are valuable in characterizing this impairment, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results